Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience

Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience

Introduction and objectives: Immune Checkpoint Inhibitors (ICI) have shifted the paradigm of cancer therapy treatment. Despite their efficacy, ICIs may induce immune-related adverse events (irAE), which can affect various organs, namely the liver. This study intends to perform a comprehensive clinic...

Full description

Bibliographic Details
Main Authors:	Joana Alves da Silva, Daniela Falcão, Cláudia Cardoso, Ana Luísa Pires, António Araújo, Fernando Castro-Poças
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	Annals of Hepatology
Subjects:	Immunotherapy cancer Hepatotoxicity Drug-Related Side Effects and Adverse Reactions Drug Induced Liver Injury Immune-related adverse event
Online Access:	http://www.sciencedirect.com/science/article/pii/S166526812100260X

Similar Items

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
by: Lorena Villa-Crespo, et al.
Published: (2022-02-01)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
by: Zherui Liu, et al.
Published: (2023-01-01)

Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival
by: Mariana Ornelas, et al.
Published: (2023-07-01)

Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis
by: Zhe Zhao, et al.
Published: (2023-06-01)

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
by: Sung Wook Hwang, et al.
Published: (2023-10-01)

Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology
by: Julian Hercun, et al.
Published: (2022-06-01)

Immune checkpoint inhibitors⁃related nervous system adverse events
by: WANG Ze⁃yi, et al.
Published: (2022-09-01)

Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience
by: Baptiste Bonnet, et al.
Published: (2024-02-01)

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
by: Prasanna Duraisamy, et al.
Published: (2023-07-01)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
by: Alisa Lepper, et al.
Published: (2023-12-01)

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
by: Katharina Leucht, et al.
Published: (2022-09-01)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
by: Kendall F. Moseley, et al.
Published: (2018-10-01)

Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study
by: Francoise Difoum, et al.
Published: (2023-07-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
by: Marcus Wölffer, et al.
Published: (2022-01-01)

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
by: Paulo Nunes Filho, et al.
Published: (2023-03-01)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
by: Florentia Dimitriou, et al.
Published: (2021-06-01)

Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature
by: Ciro Manzo, et al.
Published: (2020-11-01)

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
by: Anna Passarelli, et al.
Published: (2023-12-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
by: Xiaoxiao Ge, et al.
Published: (2023-09-01)

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center
by: Anam A. Mazharuddin, et al.
Published: (2022-11-01)

Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma
by: Victoria Purcell, et al.
Published: (2022-07-01)

Post-vaccination Symptoms with Second Dose of AstraZeneca in a Sample of Immunized Population of Ecuadorian Public Servants
by: TV Carpio Arias, et al.
Published: (2023-11-01)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
by: Roser Calvo
Published: (2019-04-01)

Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Kathryn A. Lai, et al.
Published: (2020-11-01)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
by: Jia Liu, et al.
Published: (2022-10-01)

Intervenciones educacionales para incrementar la farmacovigilancia en una unidad de salud de familia
by: Ana Rita Ribeiro Barbosa, et al.
Published: (2022-09-01)

Effectiveness and safety of protease inhibitors for the hepatitis C treatment in a hospital of South Brazil: real life data
by: Aline Bianca Borba Mattana, et al.
Published: (2020-04-01)

Age-Associated Risk of Liver-Related Adverse Drug Reactions
by: Yan-zhong Han, et al.
Published: (2022-03-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors
by: Oren Levine, et al.
Published: (2017-08-01)

Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids
by: Maroun Sadek, et al.
Published: (2020-02-01)

Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report
by: James Fletcher, MBBS, et al.
Published: (2022-11-01)

Ocular Inflammation Induced by Immune Checkpoint Inhibitors
by: Florence Chaudot, et al.
Published: (2022-08-01)

Progress in Application of TNF-α Inhibitors in Immune Checkpoint Therapy
by: ZHAO Jianrong, et al.
Published: (2021-04-01)

Reacciones adversas a medicamentos en una población colombiana, 2007-2013: análisis de bases de datos
by: Jorge Enrique Machado-Alba, et al.
Published: (2016-03-01)

Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
by: Jingting Wang, et al.
Published: (2024-01-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)